AccurayARAY -16.53%44 Days Payable is 55.24 as of Mar. 2026, which is 59% above its 10-year median of 34.73. GuruFocus rates ARAY with a GF Score™ of 44/100 and a GF Value™ of $1.34 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Accuray ranks worse than 65.53% on this metric.
Accuray's average Accounts Payable for the
three
months ended in Mar. 2026 was $48.2 Mil. Accuray's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $79.6 Mil.
Hence, Accuray's Days Payable for the
three
months ended in Mar. 2026 was 55.24.
The historical rank and industry rank for Accuray's Days Payable or its related term are showing as below:
ARAY'
s Days Payable Range Over the Past 10 Years
Min: 21.53 Med: 34.73 Max: 50.98
Current: 50.98
During the past 13 years, Accuray's highest Days Payable was 50.98. The lowest was 21.53. And the median was 34.73.
ARAY's Days Payable is ranked worse than 65.53% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs ARAY: 50.98
Accuray's Days Payable
declined
from Mar. 2025 (56.08) to Mar. 2026 (55.24).
It may suggest that Accurayaccelerated paying its suppliers.
Accuray Days Payable Related Terms
Accuray Days Payable Historical Data
* Premium members only.
The historical data trend for Accuray's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Accuray's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accuray Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Accuray's Days Payable distribution charts can be found below:
* The bar in red indicates where Accuray's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Accuray's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accuray (ARAY) has a Days Payable of 55.24 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Accuray and its competitors. This is 59% above median its historical median of 34.73. Over the past decade, Accuray's Days Payable has ranged from 21.53 to 50.98. According to the industry distribution chart, Accuray ranks #521 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 65.5%.
Is Accuray's Days Payable too high?
Accuray's current Days Payable of 55.24 is 59% above median its 10-year median of 34.73. Over the past 10 years, this metric has ranged from a low of 21.53 to a high of 50.98. The Medical Devices & Instruments industry median Days Payable is 67.87. Accuray's value of 55.24 is 18.6% below this industry median. Based on the distribution chart, Accuray ranks #521 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Accuray has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Accuray's Days Payable compare to PAVM and BDMD?
According to the Medical Devices & Instruments industry distribution chart, Accuray ranks #521 out of 795 companies for Days Payable. This places Accuray in the lower half of its industry. The industry median Days Payable is 67.87. Accuray's value of 55.24 is 18.6% below this benchmark. Historically, Accuray's own Days Payable has ranged from 21.53 to 50.98 over the past decade. While the company's 10-year median is 34.73 vs. the industry median of 67.87, Accuray has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accuray's current Days Payable of 55.24 is 18.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Accuray and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accuray's current Days Payable is 55.24, which is 59% above median its own 10-year median of 34.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accuray stock overvalued right now?
Based on GuruFocus' analysis, Accuray (ARAY) is currently considered Possible Value Trap. The stock's GF Value™ is $1.34, compared to a current price of $0.26 — trading 80.3% below its estimated fair value. The current Days Payable is 55.24, which is 59% above median its 10-year median of 34.73 and 18.6% below the Medical Devices & Instruments industry median of 67.87. Accuray's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Accuray (ARAY), the current Days Payable is 55.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Accuray (ARAY) Overvalued in 2026?
Based on GuruFocus' analysis, Accuray stock appears to be undervalued.
The current stock price of $0.26 is trading 80.3% below its estimated GF Value™ of $1.34.
GuruFocus considers Accuray to be Possible Value Trap.
Key valuation signals for ARAY:
Days Payable: 55.24 (59% above median its 10-year median of 34.73)
GF Value™: $1.34 vs. price of $0.26 (80.3% below fair value)
Industry Position: 18.6% below the Medical Devices & Instruments median (#521 of 795)
No single metric tells the full story. See the ARAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
44GF Score
Get the complete analysis for ARAY
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARAY has been successfully added to your 
